# Amneal Pharmaceuticals, Inc. (AMRX) FY2026 Q2 P&L / Income Statement

- Company: Amneal Pharmaceuticals, Inc. (AMRX)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-06, accession number 0001723128-26-000031
- Page: https://plicit.ai/financials/amrx/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/amrx-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Business Segment by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenue**: 796,197,000 US dollars
- **Cost of goods sold**: 461,689,000 US dollars
- **Gross profit**: 334,508,000 US dollars
- **Operating costs, net of other operating items (calculated)**: 204,739,000 US dollars
- **Operating income**: 129,769,000 US dollars
- **Total other expense, net**: negative 58,779,000 US dollars
- **Income before income taxes**: 70,990,000 US dollars
- **Provision for income taxes**: 1,376,000 US dollars
- **Net income**: 69,614,000 US dollars
- **Affordable Medicines - Biosimilar**: 29,128,000 US dollars
- **Affordable Medicines - Auto-Injector**: 62,214,000 US dollars
- **Affordable Medicines - Injectable**: 56,783,000 US dollars
- **Affordable Medicines - International**: 7,613,000 US dollars
- **Affordable Medicines - Oral liquid**: 10,371,000 US dollars
- **Affordable Medicines - Oral solid**: 175,172,000 US dollars
- **Affordable Medicines - Other dosage forms**: 81,594,000 US dollars
- **Affordable Medicines - Transdermal**: 67,038,000 US dollars
- **AvKARE - Government label**: 50,207,000 US dollars
- **AvKARE - Institutional**: 12,112,000 US dollars
- **AvKARE - Distribution**: 86,930,000 US dollars
- **AvKARE - Other**: 7,740,000 US dollars
- **Specialty - Central nervous system**: 95,344,000 US dollars
- **Specialty - Hormonal / allergy**: 42,099,000 US dollars
- **Specialty - License agreement**: 0 US dollars
- **Specialty - Other therapeutic classes**: 11,852,000 US dollars
- **Selling, general and administrative**: 148,722,000 US dollars
- **Research and development**: 39,017,000 US dollars
- **Intellectual property legal development expenses**: 2,087,000 US dollars
- **Restructuring and other charges**: 554,000 US dollars
- **Acquisition costs**: 7,600,000 US dollars
- **Other operating income**: negative 1,298,000 US dollars
- **Charges (credit) related to legal matters, net**: 8,057,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Amneal Pharmaceuticals, Inc.: $57.66 M; to noncontrolling interests: $11.95 M.

## Chart details: Revenue by Business Segment

- Page: https://plicit.ai/financials/amrx/fy2026-q2-income-statement/revenue-by-business-segment
- Chart image: https://plicit.ai/charts/amrx-fy2026-q2-revenue-by-business-segment-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenue**: 796,197,000 US dollars
- **Cost of goods sold**: 461,689,000 US dollars
- **Gross profit**: 334,508,000 US dollars
- **Operating costs, net of other operating items (calculated)**: 204,739,000 US dollars
- **Operating income**: 129,769,000 US dollars
- **Total other expense, net**: negative 58,779,000 US dollars
- **Income before income taxes**: 70,990,000 US dollars
- **Provision for income taxes**: 1,376,000 US dollars
- **Net income**: 69,614,000 US dollars
- **Affordable Medicines**: 489,913,000 US dollars
- **Specialty**: 149,295,000 US dollars
- **AvKARE**: 156,989,000 US dollars
- **Selling, general and administrative**: 148,722,000 US dollars
- **Research and development**: 39,017,000 US dollars
- **Intellectual property legal development expenses**: 2,087,000 US dollars
- **Restructuring and other charges**: 554,000 US dollars
- **Acquisition costs**: 7,600,000 US dollars
- **Other operating income**: negative 1,298,000 US dollars
- **Charges (credit) related to legal matters, net**: 8,057,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Amneal Pharmaceuticals, Inc.: $57.66 M; to noncontrolling interests: $11.95 M.